drugset / Trial / NCT00004827

Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa

NCT00004827

Completed 46 enrolled Retina Foundation of the Southwest
RandomizedParallel-groupDouble-blindTreatment

Summary

OBJECTIVES: I. Evaluate the potential of nutritional docosahexaenoic acid (DHA) supplementation to normalize the level of DHA in red blood cells, and to retard the progression of visual function loss in patients with early stage X-linked retinitis pigmentosa.

Timeline

Start
1996-03
Primary completion
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Subject DOCONEXENT Other / unclassified Oral

Indications